Follow us on Twitter
twitter icon@FreshPatents


Ocular Implant patents

      

This page is updated frequently with new Ocular Implant-related patent applications.




 Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof patent thumbnailBiodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof
Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers.
Allergan, Inc.


 Ocular implant container patent thumbnailOcular implant container
An implant container for containing an ocular implant is described herein. The implant container can releasably couple to an implant delivery device and provide at least partial alignment of the delivery device with an ocular implant during loading of the ocular implant onto the delivery device..
Novartis Ag


 Hypotensive lipid-containing biodegradable intraocular implants and related implants patent thumbnailHypotensive lipid-containing biodegradable intraocular implants and related implants
Biocompatible intraocular implants include a prostamide component and a biodegradable polymer that is effective in facilitating release of the prostamide component into an eye for an extended period of time. The prostamide component may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers.
Allergan, Inc.


 Prostamide-containing intraocular implants and methods of use thereof patent thumbnailProstamide-containing intraocular implants and methods of use thereof
Prostamide-containing intraocular implants that biodegrade in the eye and that are effective for reducing intraocular pressure in an eye for a sustained period. The implants generally contain a prostamide, such as bimatoprost, and at least three distinct biodegradable polymers selected from polylactide and poly(lactide-co-glycolide) polymers and are optimized for placement in and compatibility with the anterior chamber of the eye, particularly the anterior chamber angle.
Allergan, Inc.


 Sustained drug delivery implant patent thumbnailSustained drug delivery implant
Biocompatible intraocular implants may include a brimonidine free base and a biodegradable polymer associated with the brimonidine free base to facilitate the release of the brimonidine free base into an eye with the polymer matrix lasts a period of time of not more than twice the drug release duration, but more than the drug release duration.. .
Allergan, Inc.


 Punctal plug with active agent patent thumbnailPunctal plug with active agent
A method and apparatus for administering an active agent such as a medicine to a subject, uses an ocular implant such as a punctal plug, to which the active agent has been applied. The implant is installed at the eye of the subject for administering the active agent via tissues of the eye..
Mati Therapeutics Inc.


 Ocular implant insertion apparatus and methods patent thumbnailOcular implant insertion apparatus and methods
An exemplary ocular implant insertion system includes a case and a preloaded ocular implant insertion apparatus. The apparatus includes first and second movable structures that move the ocular implant in a predetermined sequence.
Hoya Corporation


 Biocompatible biodegradable intraocular implant system patent thumbnailBiocompatible biodegradable intraocular implant system
Generally, an intraocular implant and methods for treating an ocular condition. As to certain embodiments, an intraocular biocompatible biodegradable implant (11) which can provide a biocompatible biodegradable material in the form of a flexible membrane (12) containing an active agent (24) which implanted between an intraocular lens (8) and the surface of the posterior capsule (5) of the eye (1)(4) inhibits migration of residual lens epithelial cells after cataract surgery by providing structural or pharmaceutical barriers to reduce posterior capsule (5) opacification of the eye (1)(4)..
Insight Innovations, Llc


 Glaucoma drainage implant patent thumbnailGlaucoma drainage implant
The invention relates to an ocular implant for treating glaucoma. The problem addressed by the invention is to make it possible to drain aqueous humor from the anterior chamber of the eye into the subconjunctival or suprachoroidal space in order to lower the intraocular pressure in glaucoma cases.
Universitaet Rostock


 Ocular implants configured to store and release stable drug formulations patent thumbnailOcular implants configured to store and release stable drug formulations
Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. In several embodiments, the devices are configured to release a pro-drug form of a drug into a target tissue site, wherein the pro-drug is converted to an active drug that yields a therapeutic effect.
Glaukos Corporation


Hypotensive lipid-containing biodegradable intraocular implants and related methods

Biocompatible intraocular implants include a prostamide component and a biodegradable polymer that is effective in facilitating release of the prostamide component into an eye for an extended period of time. The prostamide component may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers.
Allergan, Inc.

Intracameral implant for treatment of an ocular condition

The disclosure teaches precisely engineered biodegradable drug delivery systems and methods of making and utilizing such systems. In aspects, the biodegradable drug delivery systems taught herein comprise ocular implants having a desired extended drug release profile suitable for treating elevated intraocular pressure..
Envisia Therapeutics Inc.

Intraocular implants and methods and kits therefor

Devices, methods and kits are described for reducing intraocular pressure. The devices include a support that is implantable within schlemm's canal and maintains the patency of the canal without substantially interfering with transmural fluid flow across the canal.
Sight Sciences, Inc.

Adjustable intraocular implant

Methods and devices for adjusting or configuring the flow rate of an intraocular shunt are provided whereby hypotony can be avoided by increasing the flow rate through the device. In some embodiments, the device is a shunt that can have a first flow that can be modified to a second flow by modifying the shunt, such as by cutting the shunt.
Aquesys, Inc.

Ocular implants for delivery into an anterior chamber of the eye

An ocular implant adapted to be disposed within schlemm's canal of a human eye with a body extending along a curved longitudinal central axis in a curvature plane, a first strut on one side of the implant and a second strut on an opposite side of the implant, the circumferential extent of the first strut with respect to the plane of curvature being greater than the circumferential extent of the second strut with respect to the plane of curvature. The invention also includes methods of using the implant..

Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods

Biocompatible intraocular implants, such as microparticles, include a prostamide component and a biodegradable polymer that is effective in facilitating release of the prostamide component into an eye for an extended period of time. The prostamide component may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers.
Allergan, Inc.

Steroid-containing sustained release intraocular implants and related methods

Biocompatible intraocular implants include a steroid and an auxiliary agent, where the auxiliary agent is present in an amount sufficient to lessen the severity of at least one side effect compared to the use of an otherwise identical implant lacking said auxiliary agent. The steroid and the auxiliary agent may be present on the same intraocular implant or on different implants.
Allergan, Inc.

Process for manufacturing an intraocular lens with an embedded mask

Intraocular implants and methods of making intraocular implants are provided. The intraocular implant can include a mask adapted to increase depth of focus.
Acufocus, Inc.

Methods and devices for increasing aqueous humor outflow

An ocular implant having an inlet portion and a schlemm's canal portion distal to the inlet portion, the inlet portion being disposed at a proximal end of the implant and sized and configured to be placed within an anterior chamber of a human eye, the schlemm's canal portion being arranged and configured to be disposed within schlemm's canal of the eye when the inlet portion is disposed in the anterior chamber.. .

Biodegradable ocular implant

Provided is a biodegradable ocular implant for sustained drug delivery, including a first layer comprising a first biodegradable polymer, wherein the first layer contains a drug dispersed or dissolved therein. A multi-layered biodegradable ocular implant is also disclosed..
Singapore Health Services Pte Ltd

Extraocular epiretinal implant

A visual prosthesis in the form of a retinal implant, which is distinguished by the least possible space requirement inside the eye, is achieved by a visual prosthesis having an intraocular implant and an extraocular implant, which supplies the intraocular implant with energy and controls it. Virtually all the electronic components, which do not necessarily need to be accommodated with the intraocular implant inside the eye, can be arranged outside the eyeball, for example on the sclera.
Pixium Vision Sa

Prostamide-containing intraocular implant

Prostamide-containing biodegradable intraocular implants, prostamide compounds, prostamide-containing pharmaceutical compositions, and methods for making and using such implants and compositions for the immediate and sustained reduction of intraocular pressure and treatment of glaucoma in an eye of a patient are described.. .
Allergan, Inc.

Biodegradable intravitreal tyrosine kinase implants

Biocompatible intraocular implants include a tyrosine kinase inhibitor and a biodegradable polymer that is effective to facilitate release of the tyrosine kinase inhibitor into the vitreous of an eye for an extended period of time. The therapeutic agents of the implants may be associated with a biodegradable polymer matrix, such as a matrix that is substantially free of a polyvinyl alcohol.
Allergan, Inc.

Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor

Methods for reducing or preventing transplant rejection in the eye of an individual are described, comprising: a) performing an ocular transplant procedure; and b) implanting in the eye a bioerodible drug delivery system comprising an immunosuppressive agent and a bioerodible polymer.. .
Allergan, Inc.

Ocular implant insertion apparatus and methods

An exemplary ocular implant insertion system includes a case and a preloaded ocular implant insertion apparatus. The apparatus includes first and second movable structures that move the ocular implant in a predetermined sequence.
Hoya Corporation

Crystalline forms of bimatoprost acid, methods for preparation, and methods for use thereof

The invention provides new crystalline forms of 7-[3,5-dihydroxy-2-(3-hydroxy-5-phenyl-pent-1-enyl)-cyclopentyl]-hept-5-enoic acid. This compound is commonly referred to as “bimatoprost acid.” the novel crystalline forms are designated forms i, ii, and iii.

Ocular implant delivery systems and methods

Described herein are delivery devices and methods of using the devices for delivering an ocular implant into a suprachoroidal space without use of a goniolens. The delivery device includes a handle including a channel extending from a proximal end of the handle to a distal end of the handle, an applier coupled to the handle, the applier including a blunt distal tip and an elongate, flexible wire insertable through a fluid channel of an ocular implant, and a fiber optic image bundle reversibly inserted through the channel such that the fiber optic image bundle extends to a region proximal to the blunt distal tip of the applier..

Ocular implant with therapeutic agents and methods thereof

Implants and methods for treating ocular disorders are provided. One method involves introducing an implant into an anterior chamber of an eye.

Ocular therapeutic agent delivery devices and methods for making and using such devices

ocular implant devices (10, 20, 121) for the delivery of a therapeutic agent to an eye (101, 301) in a controlled and sustained manner. Dual mode and single mode drug delivery devices (10, 20, 121) are illustrated and described.
United States Of America, Department Of Health & Human Services, Represented By The Secretary, C/o

System and delivering multiple ocular implants

Systems and methods for delivering multiple ocular implants to reduce intraocular pressure are disclosed. The ocular implants can be implanted at multiple sites within a single human eye without requiring removal of the delivery apparatus from the eye.
Glaukos Corporation

Composition for intraocular implantation of bevacizumab

A solid, compressed pharmaceutical composition comprises i) a peptide active pharmaceutical ingredient, ii) a polysaccharide excipient and/or an albumin, and iii) an oligosaccharide excipient. The polysaccharide excipient may be hyaluronic acid, or the potassium salt thereof, and the oligosaccharide excipient may be trehalose..
Ucl Business Plc

Delivery system for ocular implant

A delivery system is disclosed which can be used to deliver an ocular implant into a target location within the eye via an ab interno procedure. In some embodiments, the implant can provide fluid communication between the anterior chamber and the suprachoroidal or supraciliary space while in an implanted state.
Transcend Medical, Inc.

Reprogrammable tuneable liquid crystal lens intraocular implant and methods therefor

A reprogrammable intraocular adaptive lens prosthesis apparatus is provided. The apparatus includes a tunable liquid crystal lens (tlcl) encapsulated in the intraocular prosthesis with control electronics and a power source or in the intraocular prosthesis with a control signal receiver while an external control electronics package transmits the control signal.

Ocular system with anchoring implant and therapeutic agent

Ocular implants, delivery devices and methods for treating ocular disorders are disclosed. One method involves inserting an implant on one side of an eye.



Ocular Implant topics:
  • Ocular Implant
  • Intraocular
  • Anterior Chamber
  • Ocular Implants
  • Intraocular Pressure
  • Anterior Chamber Of The Eye
  • Implantation
  • Biodegradable
  • Drug Delivery System
  • Bevacizumab
  • Medical Device
  • Multiple Stents
  • Aqueous Humor
  • Visualization
  • Instruments


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to Ocular Implant for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Ocular Implant with additional patents listed. Browse our RSS directory or Search for other possible listings.


    2.5752

    file didn't exist2615

    479197 - 0 - 52